DSM, NKT Ink Development Contract

DSM Biologics has signed a contract with NKT Therapeutics, Inc. for the process development and cGMP manufacture of NKT’s lead product iNKT mAb. NKT, based in Waltham, MA, is a biotechnology company that focuses on developing therapeutics based on immune cells called natural killer T (NKT) cells. Financial terms of the contract were not disclosed.

NKT cells are a central part of the immune system. When exposed to microbial and viral pathogens, NKT cells secrete high levels of specific cytokines, which stimulate the immune system to eliminate pathogens.

Karen King, president of DSM Biologics, said, “We are delighted to be working with NKT Therapeutics, based in the U.S., from our European biomanufacturing operations in Groningen, the Netherlands.We are truly honored to be supporting their first clinical program from our cGMP operations.”

Dr. Robert Mashal, president and chief executive officer of NKT Therapeutics, said, “For NKT, advancing our lead program into cGMP manufacturing marks a significant milestone for the company, and we are certain we have found the right partner in DSM.”


Click here to learn more about DSM.